Price
$72.97-2.81%Social Signal Score
Analyst Ratings
32 analysts52-week range
- Last close
- $72.97
- Off 52w high
- -53.5%
- 200-day average
- $106.60
- vs 200-day
- -31.5%
Revenue
$2.47B+98.87%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kristin C. Peck
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 14,500
- Beta
- 0.73
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 4.56
Financials
Revenue
$2.47B+98.9%Net Income
$691.00M+189.1%EBITDA
$927.00M+113.6%Free Cash Flow
$538.00M+195.6%EPS (diluted)
$1.65+243.8%Shares Outstanding (diluted)
417.70M-16.1%Operating Expenses
$765.00MCash & Debt
$1.68BReturn of Capital
$807.00MRevenue by Segment (annual)
$9.26BDividend per Share
$0.53Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $9.47B | $2.67B | $6.03 |
| 2024 | $9.26B | $2.49B | $5.47 |
| 2023 | $8.54B | $2.34B | $5.08 |
| 2022 | $8.08B | $2.11B | $4.51 |
| 2021 | $7.78B | $2.04B | $4.29 |
| 2020 | $6.67B | $1.64B | $3.44 |
| 2019 | $6.26B | $1.50B | $3.14 |
| 2018 | $5.83B | $1.43B | $2.96 |
| 2017 | $5.31B | $864.00M | $1.76 |
| 2016 | $4.89B | $821.00M | $1.66 |
| 2015 | $4.76B | $339.00M | $0.68 |
| 2014 | $4.79B | $583.00M | $1.16 |
| 2013 | $4.56B | $504.00M | $1.01 |
| 2012 | $4.34B | $436.00M | $0.87 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ZTS's reported EPS growth of 16.1% a year over 13 years.
- EPS in 5 years
- $12.72
- Implied price
- $267.02
- Return from $69.69
- 30.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $132.76 — today's price is already 47.5% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 15 | 18 | 21 | 24 | 27 |
|---|---|---|---|---|---|
| 6.1% | 11.8% | 15.9% | 19.6% | 22.8% | 25.7% |
| 11.1% | 17.0% | 21.4% | 25.2% | 28.6% | 31.6% |
| 16.1% | 22.3% | 26.8% | 30.8% | 34.4% | 37.6% |
| 21.1% | 27.6% | 32.3% | 36.5% | 40.1% | 43.5% |
| 26.1% | 32.8% | 37.8% | 42.1% | 45.9% | 49.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
47-46.55%Social Signal Score
Mentions (34)
- Newszacks.com·4d ago·Neutral
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why Zoetis (ZTS) reached $69.1 at the closing of the latest trading day, reflecting a -1.05% change compared to its last close.
View source ↗ - News (RSS)seekingalpha·5d ago·Neutral
Zoetis: Priced For The Worst, Worth Buying
View source ↗ - Newsseekingalpha.com·6d ago·Neutral
Zoetis: Priced For The Worst, Worth Buying Zoetis Inc. (ZTS) has fallen 71% from its 2021 peak, now trading at 2017 levels, as pricing power eroded and pet medicine volumes declined. Despite near-term headwinds, Zoetis maintains industry-leading margins and is positioned to weather price wars better than rivals due to its product mix and scale. Patent expiries for Apoquel and Simparica in 2030/2032 are key risks, but a robust pipeline of 12 candidates could offset revenue losses if half succeed.
View source ↗ - Newszacks.com·11d ago·Neutral
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.
View source ↗ - Newsbusinesswire.com·12d ago·Neutral
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts. Investors and the…
View source ↗ - Newszacks.com·17d ago·Positive
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day.
View source ↗ - News (RSS)seekingalpha·17d ago·Negative
Zoetis: The Worst May Be Priced In
View source ↗ - Newsseekingalpha.com·17d ago·Negative
Zoetis: The Worst May Be Priced In Zoetis faces ongoing headwinds but is now considered a cautious 'Buy' as valuation reflects low-to-mid single-digit growth potential. Q2 results disappointed, with flat revenues and declining U.S. sales, but international and livestock segments showed resilience and growth. Management revised 2026 guidance downward, but ZTS's low valuation multiples and aggressive share buybacks support its fair value case.
View source ↗ - Newsmarketbeat.com·18d ago·Negative
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales Zoetis NYSE: ZTS executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides.
View source ↗ - News (RSS)seekingalpha·18d ago·Positive
Zoetis: An Undervalued Compounder Hiding In Plain Sight
View source ↗ - News (RSS)seekingalpha·19d ago·Neutral
Zoetis: New Competition Changes The Story, But Not Yet The Rating
View source ↗ - News (Marketaux)seekingalpha.com·19d ago·Neutral
Zoetis Stock: New Competition Changes The Story, But Not Yet The Rating (NYSE:ZTS) Zoetis ( ZTS ) still remains on[+181 characters]
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Zoetis: An Undervalued Compounder Hiding In Plain Sight Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my DCF valuation. ZTS faces near-term pressure from weaker U.S. companion animal demand, increased competition, and margin compression due to promotions and rebates. Long-term growth is supported by structural pet humanization trends, international expansion, a robust R&D pipeline, and a growing diagnostics segment.
View source ↗ - News (Marketaux)gurufocus.com·21d ago·Positive
Zoetis Inc at Morgan Stanley Global Healthcare Conference Transcript We're happy to have Zoetis with[+212 characters]
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)yahoo·27d ago·Neutral
Zoetis (ZTS) Shares Drop After Earnings Revision
View source ↗ - Newsbusinesswire.com·34d ago·Neutral
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET. Interested parties can access the live audio webcast …
View source ↗ - News (RSS)seekingalpha·36d ago·Neutral
Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead
View source ↗ - Newsseekingalpha.com·37d ago·Neutral
Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead Phibro Animal Health's Zoetis MFA acquisition has created a larger animal health platform with stronger earnings and broader manufacturing reach. Vaccines, nutritional specialties, and companion-animal expansion give PAHC newer growth verticals beyond the legacy MFA franchise. Management's optimization program and Chicago Heights consolidation could improve efficiency as the acquired portfolio moves beyond integration.
View source ↗ - News (Marketaux)gurufocus.com·39d ago·Positive
A Look at Zoetis Inc (ZTS) After 3.2% Decline -- GF Value $180.60 vs Price $75.02 On August 27, 2026, Zoetis [+256 characters]
View source ↗ - News (RSS)yahoo·43d ago·Neutral
Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
View source ↗ - News (RSS)yahoo·43d ago·Neutral
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
View source ↗ - Newsseekingalpha.com·49d ago·Neutral
Zoetis: A Solid Long-Term Buy After Harsh Drawdown Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic traffic and heightened competition across key companion animal franchises. Despite aggressive competitor promotions, Zoetis protects industry-leading profitability (35%–37% EBIT margins) using targeted gross-to-net rebates rather than base list-price cuts. Trading at a historic low 12x P/E and a 7%+ FCF yield, Zoetis offers a strong margin of safety…
View source ↗ - News (RSS)seekingalpha·50d ago·Neutral
Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap
View source ↗ - Newsseekingalpha.com·51d ago·Neutral
Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap Zoetis' Q2 earnings results were mixed, and the company cut its forward guidance. This has reduced the stock's margin of safety, but on balance, the risk/reward profile still favors the bulls. Zoetis has other segments performing well which partially offset the weakness in U.S. pet-related sales.
View source ↗ - 4chan /biz/biz·52d ago·Neutral
…rns-calculator https://brokerchooser.com/ https://www.chathamfinancial.com/technology/us-market-rates https://iran.liveuamap.com/ >Featured stock of the thread NYSE:ZTS Zoetis Inc >Preivous >>62594031
View source ↗ - 4chan /biz/biz·52d ago·Neutral
…rns-calculator https://brokerchooser.com/ https://www.chathamfinancial.com/technology/us-market-rates https://iran.liveuamap.com/ >Featured stock of the thread NYSE:ZTS Zoetis Inc >Preivous >>62594031
View source ↗ - Newsseekingalpha.com·52d ago·Neutral
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite …
View source ↗ - News (RSS)yahoo·52d ago·Neutral
Zoetis (ZTS) Remains a Leader, So Why Was It Sold?
View source ↗ - News (RSS)investing·53d ago·Neutral
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
View source ↗ - Newsreuters.com·53d ago·Negative
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs The U.S. Food and Drug Administration on Thursday issued an emergency use authorization for Zoetis' flea and tick drug to treat New World screwworm (NWS) infestations in dogs and puppies.
View source ↗ - 4chan /biz/biz·53d ago·Neutral
>>62590170 *ZTS >>62590187 still its a pretty brutal pull back
View source ↗ - News (Marketaux)finance.yahoo.com·57d ago·Positive
Zoetis Q2 Earnings Call Highlights Zoetis lowered its full-year ou[+113 characters]
View source ↗ - Newsmarketbeat.com·57d ago·Neutral
Zoetis Q2 Earnings Call Highlights Zoetis NYSE: ZTS reported second-quarter revenue of $2.5 billion, flat on a reported basis and down 1% organically, as pressure in U.S. companion-animal categories offset growth in livestock, diagnostics and international markets. Adjusted net income was $781 million, down 2% organically, while adjusted diluted earnings per share rose 4% to $1.87, benefiting from a lower share count following share repurchases.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $1.52 per share
Typical surprise +4.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$1.87 vs $1.85beat
- Thu, May 7$1.53 vs $1.60miss
- Thu, Feb 12$1.48 vs $1.40beat
- Tue, Nov 4$1.70 vs $1.62beat
- Tue, Aug 5$1.76 vs $1.62beat
- Tue, May 6$1.48 vs $1.41beat
Estimates and results for ZTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZTS officers and directors.
- Bought
- $886k
- Sold
- —
3 trades
0 trades
- Damelio Frank Abought
- Bisaro Paulbought
- Mccallister Michael Bbought
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 7, 2026 (52d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (36d later)Buy$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Jul 16, 2026 (37d later)Buy$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Jul 16, 2026 (37d later)Buy$1,001 - $15,000
- Chuck Fleischmannhouse · TN03 · disclosed Jul 13, 2026 (34d later)Buy$15,001 - $50,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jul 3, 2026 (17d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 11, 2026 (41d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 11, 2026 (27d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (26d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Mar 10, 2026 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (28d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 12, 2026 (24d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2025 (27d later)Buy$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Dec 5, 2025 (25d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (38d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (18d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (18d later)Buy$1,001 - $15,000
- Richard Ray Larsenhouse · WA02 · disclosed Oct 17, 2025 (11d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (18d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.